e-ISSN: Pending
Negative / Null Result ReportOpen accessTherapeutics. Pharmacology

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Shih-Wei Lai; Shih-Wei Lai; Cheng-Li Lin; Cheng-Li Lin; Kuan-Fu Liao; Kuan-Fu Liao · 2017 · Frontiers in Pharmacology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem wa

Abstract by Shih-Wei Lai; Shih-Wei Lai; Cheng-Li Lin; Cheng-Li Lin; Kuan-Fu Liao; Kuan-Fu Liao, Frontiers in Pharmacology (2017) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.3389/fphar.2017.00767